Merck Eyes $5B Flu Drug, Unaffected by Vaccine Policy Shifts
Update: 2025-11-17
Description
Merck, the pharmaceutical giant, is eyeing a potential $5 billion opportunity with Cidara Therapeutics experimental flu drug, CD388. This long-acting antiviral treatment, not a vaccine, is in late-stage trials and could offer single-dose protection against all flu strains. Merck, after acquiring Cidara for nearly $9.2 billion, plans to launch CD388 without CDC review. Despite vaccine policy shifts in the US, Mercks CEO clarifies the acquisition is purely driven by the drugs potential.
The Daily News Now! — Every city. Every story. AI-powered.
Hosted on Acast. See acast.com/privacy for more information.
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
1.0x
